Primary endpoint met in first randomized Phase 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile More than 90% of patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results